BNTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BioNTech SE
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 10, 2026
$89.21+1.50 (+1.71%)
Close on Oct 19, 2026
BioNTech statistics
Financials through Dec 31, 2025, price-based ratios appear once a share price is available, median of Biological Products, (No Diagnostic Substances) companies for comparison
Income (trailing twelve months)
| Measure | BioNTech | Industry median |
|---|---|---|
| Revenue | €2.87B | €447.40M |
| Gross Profit | €2.23B | €1.08B |
| Operating Income | -€1.40B | -€68.03M |
| Pretax Income | -€1.05B | -€49.18M |
| Net Income | -€1.14B | -€6.53M |
| EBITDA | -€1.02B | -€48.04M |
| EPS (Diluted) | -4.70 EUR | -0.61 EUR |
Margins
| Measure | BioNTech | Industry median |
|---|---|---|
| Gross Margin | 77.6% | 42.8% |
| Operating Margin | -49.0% | -33.2% |
| Pretax Margin | -36.6% | -36.6% |
| Profit Margin | -39.6% | -31.7% |
| EBITDA Margin | -35.6% | -28.6% |
| FCF Margin | 9.79% | -24.4% |
Returns
| Measure | BioNTech | Industry median |
|---|---|---|
| Return on Assets (ROA) | -5.10% | -5.10% |
| Return on Capital Employed (ROCE) | -7.08% | -26.9% |
Growth
| Measure | BioNTech | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 4.32% | 1.99% |
| Revenue Growth (3Y CAGR) | -45.1% | 13.5% |
| Revenue Growth (5Y CAGR) | 42.9% | 11.0% |
Balance sheet
| Measure | BioNTech | Industry median |
|---|---|---|
| Cash & Short-Term Investments | €7.68B | €291.68M |
| Net Cash (Debt) | €7.68B | €87.54M |
| Net Cash Per Share | 30.55 EUR | 1.09 EUR |
| Working Capital | €14.00B | €121.78M |
Financial position
| Measure | BioNTech | Industry median |
|---|---|---|
| Current Ratio | 7.54 | 2.81 |
| Quick Ratio | 4.01 | 1.23 |
| Interest Coverage | -20.13 | -0.90 |
Cash flow (trailing twelve months)
| Measure | BioNTech | Industry median |
|---|---|---|
| Operating Cash Flow | €456.00M | -€35.31M |
| Capital Expenditures | -€175.10M | -€4.42M |
| Free Cash Flow | €280.90M | -€53.81M |
| FCF Per Share | 1.12 EUR | -0.56 EUR |
Efficiency
| Measure | BioNTech | Industry median |
|---|---|---|
| Asset Turnover | 0.13 | 0.32 |
| Inventory Turnover | 3.26 | 1.33 |
| Revenue Per Employee | €5.74M | €420.86K |
| Profits Per Employee | -€2.27M | -€247.02K |
| Employee Count | 500 | 378 |
Shares
| Measure | BioNTech | Industry median |
|---|---|---|
| Shares Outstanding | 251,204,000 | 105,361,000 |
| Shares Change (YoY) | 0.54% | 6.28% |
| Float | 105,142,000 | 78,574,400 |
| Shares Held by Insiders | 58.1% | 9.05% |
| Shares Held by Institutions | 18.9% | 13.8% |
Taxes
| Measure | BioNTech | Industry median |
|---|---|---|
| Income Tax | €85.30M | €1.53M |
Scores
| Measure | BioNTech | Industry median |
|---|---|---|
| Piotroski F-Score | 5 | 5 |
Calculated by StockData from BioNTech's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.